{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260623312556/en/VS-7375-Demonstrates-Clinical-Activity-with-a-Favorable-Safety-and-Tolerability-Profile-in-TARGET-D-101-Phase-12-Clinical-Trial-in-Patients-with-Advanced-KRAS-G12D-Mutated-Solid-Tumors", "message": "News view counter 812627 successfully enlarged"}